Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9729994 | 1.00 | MAPK1 (0.38) | MAPK1ALDH1A1 | |
| SCHEMBL9635126 | 0.79 | MAPK1 (0.36) | MAPK1ALDH1A1 | |
| SCHEMBL13203566 | 0.77 | MAPK1 (0.35) | MAPK1 | |
| SCHEMBL7762970 | 0.75 | MAPK1 (0.38) | MAPK1ALDH1A1 | |
| SCHEMBL14321410 | 0.75 | — | — | |
| SCHEMBL12013699 | 0.73 | — | — | |
| SCHEMBL16168465 | 0.73 | — | — | |
| SCHEMBL2736104 | 0.73 | — | — | |
| SCHEMBL35821 | 0.73 | — | — | |
| SCHEMBL14300811 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977328-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-07-12 | — | — | US | disclosed |
| US-7943607-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-20110053910-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | ASTRAZENECA AB (SE) | 2011-03-03 | — | — | US | disclosed |
| US-7842694-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2010-11-30 | — | — | US | disclosed |
| US-7842694-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2010-11-30 | — | — | US | disclosed |
| US-20100160286-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | ASTRAZENECA UK LIMITED AB (SE) | 2010-06-24 | — | — | US | disclosed |
| US-7642259-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2010-01-05 | — | — | US | disclosed |
| US-7642263-B2 | Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes | ASTRAZENECA AB (SE) | 2010-01-05 | — | — | US | disclosed |
| US-20090264336-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264336-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-10-22 | — | — | US | disclosed |
| US-20090118159-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20090111790-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-04-30 | — | — | US | disclosed |
| US-20090105214-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | US | disclosed |
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105214-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | GCK, GCKR, GK | MAPK1 690/4885ALDH1A1 1289/4885 |
| US-20090029905-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | MAPK1 777/4885ALDH1A1 828/4885 |
| US-20090111790-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | MAPK1 526/4885ALDH1A1 1116/4885 |
| US-20100160286-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVES FOR THE TREATMENT OF DIABETES | GCK, GCKR, HK1 | MAPK1 461/4885ALDH1A1 789/4885 |
| US-20090118159-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | MAPK1 526/4885ALDH1A1 1116/4885 |
| US-20110053910-A1 | 2 -HETEROCYCLYLOXYBENZOYL AMINO HETEROCYCLYL COMPOUNDS AS MODULATORS OF GLUCOKINASE FOR THE TREATMENT OF TYPE 2 DIABETES | GCK, GCKR, HK1 | MAPK1 262/4885ALDH1A1 1352/4885 |
| US-20090264336-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | GCK, GCKR, GK | MAPK1 526/4885ALDH1A1 1116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.